KOSDAQBiotech & Pharma041920

Mediana

₩7,210▲ 0.14%2026-11-18 close
Market Cap
₩134.1B
Turnover
₩400M
Volume
50K
Shares out.
18.6M
PER
21.7×
PBR
1.0×
EPS
₩354
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Q3 Swing to Loss Puts Wireless Monitors in Focus

Mediana's sales and operating profit rose in both Q2 and Q3 2026, but Q3 swung to a net loss attributable to controlling shareholders of KRW 811 million, so whether the wireless patient monitoring business turns into profit is the next item to watch.

  1. 1

    Annual sales peaked at KRW 78.4 billion in 2023, fell to KRW 57 billion in 2024, and recovered to KRW 64.9 billion in 2025.

  2. 2

    Operating margin fell from 15.5% in 2022 to 2.3% in 2024 before rising to 9.2% in 2025.

  3. 3

    Net income attributable to controlling shareholders declined for three consecutive years from 2023 through 2025, reaching KRW 5.27 billion in 2025.

  4. 4

    Sales and operating profit rose for two straight quarters in Q2 and Q3 2026, but Q3 swung to a net loss attributable to controlling shareholders of KRW 811 million.

  5. 5

    Wireless patient monitoring and overseas exports are the main growth drivers, and Selvas AI and two others hold 37.77% of the shares.

02

Business structure

Mediana was founded in 1995 as a medical device maker and listed on KOSDAQ in 2014. Its core business is patient monitoring systems, including integrated monitoring solutions, alongside emergency care products centered on automated external defibrillators and vascular access catheters (VAD).

The company sells under its own brand and also runs an ODM business supplying partners. Patient monitoring is the largest revenue category, followed by defibrillators, according to a financial information site's breakdown.

Customer concentration is high: a 2023 report listed Medtronic at 29.7% and Reliance Medical at 20.6% among customers above 10% of sales. A company profile dated August 31, 2026 describes the monitoring revenue base as North America, long-term care hospitals and ODM customers.

Its new wireless patient monitoring line is set to enter the integrated wired and wireless monitoring market from 2026 through a contract with a wearable ECG maker, as described in a January 2026 Leading Investment & Securities report.

At APHRS 2026 in Busan, the company showed an integrated monitoring solution linking wearable ECG with bedside equipment. Management attributed 2025 profit improvement to market-specific targeting, generational product upgrades and in-house production of medical consumables. The largest shareholder is Selvas AI, and Selvas AI and two others held 37.77% as of October 28, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15B₩1.6B10.5%
2025Q4₩19.2B₩1.9B9.7%
2026Q1₩16.1B₩1.6B10.0%
2026Q2₩21.1B₩3B14.0%
2026Q3₩22.1B₩3.1B14.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩68.3B₩10.6B₩10.6B15.5%11.8%14.9%
2023₩78.4B₩9.4B₩8.9B12.0%8.8%11.2%
2024₩57B₩1.3B₩6.2B2.3%4.9%9.2%
2025₩64.9B₩6B₩5.3B9.2%3.9%8.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Based on disclosed annual results, sales were KRW 68.3 billion in 2022, KRW 78.4 billion in 2023, KRW 57 billion in 2024 and KRW 64.9 billion in 2025. 2023 was the largest year and 2024 the smallest. Sales fell 27.3% in 2024 and rose 13.9% in 2025.

Operating profit fell from KRW 10.6 billion in 2022 to KRW 9.4 billion in 2023 (down 11.4%) and to KRW 1.31 billion in 2024 (down 86.1%), then recovered to KRW 5.95 billion in 2025 (up 354.5%).

Operating margin was 15.5% in 2022, 12.0% in 2023, 2.3% in 2024 and 9.2% in 2025, so the margin has recovered from the 2024 low but remains below 2022.

Net income attributable to controlling shareholders was KRW 10.6 billion in 2022, KRW 8.89 billion in 2023, KRW 6.21 billion in 2024 and KRW 5.27 billion in 2025, a decline for three straight years from 2023. In 2024, operating profit was only KRW 1.31 billion while net income was KRW 6.21 billion.

A broker's 2024 financial table shows non-operating income of about KRW 6.9 billion and interest income of KRW 2.6 billion, suggesting that non-operating and financial income drove much of the gap.

Quarterly, sales rose from KRW 15 billion in Q3 2025 to KRW 19.2 billion in Q4 2025 (up 28.2% quarter on quarter), then fell to KRW 16.1 billion in Q1 2026 (down 16.4%). Sales then rose to KRW 21.1 billion in Q2 2026 (up 31.5%) and KRW 22.1 billion in Q3 2026 (up 4.7% quarter on quarter and 47.5% year on year).

Operating profit reached KRW 3.12 billion in Q3 2026, up 97.2% year on year. In the same quarter, net income attributable to controlling shareholders swung to a net loss of KRW 811 million, compared with net income of KRW 3.11 billion in Q2 2026.

Changes in non-operating items and income tax will need to be checked in the next quarterly report. Equity at the end of 2025 was KRW 135.4 billion, all attributable to controlling shareholders, and total liabilities were KRW 11.4 billion.

05

Industry analysis

Patient monitors and defibrillators follow hospital equipment investment and demand in emergency care systems. Mediana has a domestic hospital base, but its exports and ODM supply are large, so its order flow depends partly on global medical device companies.

In April 2025, Hana Securities pointed to a temporary inventory adjustment by Medtronic, an ODM customer, and analyzed it as weighing on sales. Global growth in AI, remote care and wearable medical devices is the backdrop for the company extending its products toward linking wearable ECG with bedside monitoring.

A 2023 report said the company has invested roughly KRW 6 billion to KRW 10 billion a year in R&D. On competition, the view is that rivalry with global medical device companies is unavoidable. The company has highlighted a multi-product portfolio in which weakness in one line can be offset by others.

Where the company sits in the industry cycle is hard to judge from its sales alone, so hospital investment and emergency equipment replacement cycles need to be watched. Running both its own brand and ODM supply in the same field is a feature that sets it apart.

06

Outlook

Wireless patient monitoring was presented in a January 2026 Leading Investment & Securities report as a new business that could generate sales quickly from the first quarter of 2026.

The same report cited the company's customer base of about 3,000 hospitals and overseas certifications as strengths, and suggested an early push into overseas markets. Consolidated sales rose 21.2% year on year in the first half of 2026, and operating profit rose 82.6%, according to a financial information service.

Cumulative sales from Q1 to Q3 2026 also rose from the same period a year earlier. The 2026 full-year sales estimate of KRW 106.1 billion in that January report is a forecast made at that time, and compared with the Q1 to Q3 run rate, it would require Q4 sales to exceed Q3 by a wide margin.

Operating margins in Q2 and Q3 2026 were above the 9.2% full-year 2025 margin, which supports the case for profitability recovery. However, the reading depends on whether the Q3 net loss came from non-operating items or income tax. The next periodic report is the 2026 annual report, due by March 31, 2027.

Whether additional hospital contracts for wireless monitoring and overseas partner talks are confirmed by disclosure is the key to medium-term growth. Once contracts are confirmed, how the new business's sales show up separately in quarterly results is another item to check.

07

Valuation

PER
21.7×
PBR
1.0×
ROE
4.8%
EPS
₩354
BPS
₩7,642
Dividend per share
₩0

The current share price sits in a range close to book equity, so the price-to-book premium over net assets is not large.

Earnings-based multiples read differently: net income attributable to controlling shareholders declined for three straight years from 2023 through 2025, so earnings multiples come out higher at the same share price.

Over the last four quarters, net income attributable to controlling shareholders totaled KRW 6.54 billion, and with a net loss in Q3 2026, earnings multiples depend on how results build from Q4 onward.

Cash dividends have not been recorded since 2024, so their contribution is low compared with the dividend levels of the KOSDAQ medical and precision equipment industry.

Earlier broker reports derived target multiples at a discount to industry averages, and those assumptions depend on growth assumptions for the new business. How valuation reads will depend on results from Q4 2026 onward and on how much wireless monitoring sales show up in quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wireless monitoring as a new revenue line

A January 2026 Leading Investment & Securities report viewed the new wireless monitoring business as showing growth potential through quick sales generation. The company enters the integrated wired and wireless market through a contract with a wearable ECG maker, and can use its base of about 3,000 hospital customers.

Overseas certifications were also cited as a basis for an early push abroad. This view reflects the report's date, so actual contributions need to be checked in quarterly disclosures.

Recovery in Q2 and Q3 2026

Sales and operating profit rose for two straight quarters in Q2 and Q3 2026. Q3 operating profit of KRW 3.12 billion was up 97.2% year on year, and Q3 sales of KRW 22.1 billion rose 47.5% from a year earlier.

A financial information service showed consolidated sales up 21.2% and operating profit up 82.6% in the first half of 2026. Operating margins in Q2 and Q3 exceeded the full-year 2025 level, which is cited as evidence of recovery.

Low leverage and cash flow

Total liabilities at the end of 2025 were KRW 11.4 billion, and the debt ratio fell from 14.9% in 2022 to 8.4% in 2025. Operating cash flow was KRW 9.7 billion in 2022, KRW 14.6 billion in 2023, KRW 5.11 billion in 2024 and KRW 5.5 billion in 2025, recovering after the 2024 low. This financial structure is cited as support for the capacity to invest in the new business.

09

Bear factors

Q3 swing to net loss

Net income attributable to controlling shareholders swung to a net loss of KRW 811 million in Q3 2026. This contrasts with operating profit rising to KRW 3.12 billion in the same quarter. Compared with net income of KRW 2.27 billion in Q3 2025, the direction also reversed. Whether non-operating items or income tax drove the result needs to be confirmed in the quarterly report.

Three years of profit decline and thin margins

Net income attributable to controlling shareholders declined for three straight years from 2023 through 2025, reaching KRW 5.27 billion in 2025. Operating margin fell from 15.5% in 2022 to 2.3% in 2024 and recovered to 9.2% in 2025, still below the 2022 level.

In 2024, net income was far above operating profit, so the year leaned on non-operating income. Whether core operating profit keeps recovering will be checked in the next periodic report.

Customer concentration and major shareholder stake

A high share of sales from two major customers means one customer's inventory adjustment can directly affect results. In April 2025, Hana Securities pointed to a temporary inventory adjustment at an ODM customer. Selvas AI and two others hold 37.77%, a factor to consider in trading structure. Both customer and shareholder concentration are specific to this company.

10

Risk factors

New business execution risk

It is not yet clear how much wireless monitoring sales will show up in quarterly results. The structure relies heavily on partners such as the wearable ECG maker, so the pace of contract expansion is a variable.

It also needs checking whether additional bedside contracts and overseas partner talks are confirmed by disclosure. The new business's contribution is hard to separate from the core business.

Customer concentration and ODM demand swings

With two major customers accounting for a high share of sales, a change in one customer's inventory or orders can move quarterly results sharply. The temporary ODM inventory adjustment flagged by Hana Securities in April 2025 is an example.

Competition with global medical device companies is intense, which could weigh on pricing and volume negotiations.

Earnings volatility and reliance on non-operating income

In 2024, operating profit was KRW 1.31 billion while net income was KRW 6.21 billion, so earnings leaned heavily on non-operating income. The Q3 2026 net loss is also a volatility point that can be read in the same context. Whether the earnings structure stabilizes around the core business will be checked in the next periodic report.

11

What to watch next

  1. Early February 2027 (approx.)

    Preliminary 2026 full-year results. The 2025 annual results were reported in early February 2026, so whether 2026 net income attributable to controlling shareholders exceeds the KRW 5.27 billion of 2025 is the key item.

  2. By March 31, 2027

    Submission of the 2026 annual report, the next periodic report. It will show the Q4 2026 figures and the full-year non-operating and income tax items.

  3. By May 15, 2027

    Submission of the Q1 2027 quarterly report. It will show whether wireless patient monitoring sales are reflected in quarterly results and whether operating margin holds at the Q2 and Q3 2026 level.

  4. Upon disclosure

    Whether additional bedside contracts for wireless monitoring and overseas partner agreements are disclosed. The key item is whether contract scale translates into sales contribution.

12

Overall view

Mediana's sales rose from KRW 68.3 billion in 2022 to KRW 78.4 billion in 2023, fell to KRW 57 billion in 2024 and recovered to KRW 64.9 billion in 2025. Operating profit rose from a KRW 1.31 billion low in 2024 to KRW 5.95 billion in 2025, but the 2025 operating margin of 9.2% remains below the 15.5% of 2022.

Net income attributable to controlling shareholders declined for three straight years to KRW 5.27 billion. Sales and operating profit rose for two straight quarters in Q2 and Q3 2026, and first-half figures improved. On the other hand, Q3 2026 swung to a net loss of KRW 811 million, so the direction of profit is mixed.

Wireless patient monitoring is the growth line of the new business, but how much of it shows up in quarterly results is not yet clear. Customer concentration and the 37.77% major shareholder stake are also factors to note. The next checkpoints are the 2026 annual report and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. oksiri.com
  2. butler.works
  3. comp.wisereport.co.kr
  4. investing.com
  5. leading.co.kr
  6. thinkpool.com
  7. newsprime.co.kr
  8. m.news.nate.com
  9. pharm.edaily.co.kr
  10. hanaw.com
  11. v.daum.net
  12. k5.co.kr
  13. pharm.edaily.co.kr
  14. comp.fnguide.com
  15. gminsights.com
  16. hkn24.com
  17. kind.krx.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis